Serum cystatin C and indices of lung function in elderly Chinese men with chronic obstructive pulmonary disease
- First Online:
- 104 Downloads
The aim of this cross-sectional case–control study was to determine the relationship between serum cystatin C (sCysC) levels and lung function in elderly male patients with chronic obstructive pulmonary disease (COPD).
This study included 251 Chinese men (age ≥ 65 years) who were divided into COPD (n = 129) and non-COPD (n = 122) groups. Participants underwent lung function and laboratory testing, including measurement of sCysC levels. Relationships between sCysC concentration and indices of lung function were assessed by multiple regression analysis.
Participants in the COPD group displayed higher sCysC concentrations (P = 0.041) and lower lung function (P < 0.001) compared to participants in the non-COPD group. Multiple linear regression analyses revealed that the reciprocal of the sCysC concentration (1/sCysC) was positively associated with the predicted forced expiratory volume in 1 s in all subjects (β = 0.156, P = 0.009). The findings indicate that high sCysC levels were directly associated with decreased lung function in elderly Chinese men with COPD.
High sCysC concentration may be a potential indicator of impaired lung function, and its application may improve the diagnosis and assessment of COPD severity in elderly male patients.
KeywordsCystatin C Chronic obstructive pulmonary disease Lung function Elderly patient
- 1.Global strategy for the diagnosis, management and prevention of COPD, global initiative for chronic obstructive lung Disease (GOLD) 2011 http://www.goldcopd.org/. Accessed December 2011
- 6.China’s major health challenge: control of chronic diseases (2011). Lancet 378(9790):457Google Scholar
- 15.Wanger J, Clausen JL, Coates A, Pedersen OF, Brusasco V, Burgos F, Casaburi R, Crapo R, Enright P, van der Grinten CP, Gustafsson P, Hankinson J, Jensen R, Johnson D, Macintyre N, McKay R, Miller MR, Navajas D, Pellegrino R, Viegi G (2005) Standardisation of the measurement of lung volumes. Eur Respir J 26(3):511–522PubMedCrossRefGoogle Scholar
- 20.Shastri S, Katz R, Shlipak MG, Kestenbaum B, Peralta CA, Kramer H, Jacobs DR Jr, de Boer IH, Cushman M, Siscovick D, Sarnak MJ (2011) Cystatin C and albuminuria as risk factors for development of CKD stage 3: the multi-ethnic study of atherosclerosis (MESA). Am J Kidney Dis 57(6):832–840PubMedCentralPubMedCrossRefGoogle Scholar
- 26.Deo R, Fyr CL, Fried LF, Newman AB, Harris TB, Angleman S, Green C, Kritchevsky SB, Chertow GM, Cummings SR, Shlipak MG, Health ABCs (2008) Kidney dysfunction and fatal cardiovascular disease–an association independent of atherosclerotic events: results from the health, aging, and body composition (Health ABC) study. Am Heart J 155 (1):62–68Google Scholar
- 35.Sarnak MJ, Katz R, Fried LF, Siscovick D, Kestenbaum B, Seliger S, Rifkin D, Tracy R, Newman AB, Shlipak MG, Cardiovascular Health S (2008) Cystatin C and aging success. Arch Intern Med 168 (2):147–153Google Scholar